Guidance for Aurinia Pharmaceuticals (AUPH)
| Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
|---|---|---|---|---|---|---|
| 2026 | N/A | N/A | $315.00M – 325.00M | N/A | = Maintained | Details |
| 2025 | N/A | N/A | $260.00M – 270.00M | $270.50M | = Maintained | Details |
| 2025 | N/A | N/A | $260.00M – 270.00M | $258.20M | = Maintained | Details |
| 2025 | N/A | N/A | $250.00M – 260.00M | $258.60M | = Maintained | Details |
| 2025 | N/A | N/A | $250.00M – 260.00M | $274.40M | = Maintained | Details |
| 2024 | N/A | N/A | $210.00M – 220.00M | $234.20M | = Maintained | Details |
| 2024 | N/A | N/A | $210.00M – 220.00M | $227.10M | = Maintained | Details |
| 2024 | N/A | N/A | $200.00M – 220.00M | $223.20M | = Maintained | Details |
| 2024 | N/A | N/A | $200.00M – 220.00M | $219.10M | = Maintained | Details |
| 2023 | N/A | N/A | $135.00M – 155.00M | $142.70M | = Maintained | Details |
| 2022 | N/A | N/A | $115.00M – 135.00M | $134.60M | = Maintained | Details |
| 2021 | N/A | N/A | $40.00M – 50.00M | $45.60M | = Maintained | Details |
| Q2 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
